The Inhibition of Extended Spectrum β-Lactamases: Hits and Leads

Author(s): Davide Farina, Francesca Spyrakis, Alberto Venturelli, Simon Cross, Donatella Tondi, Maria Paola Costi

Journal Name: Current Medicinal Chemistry

Volume 21 , Issue 12 , 2014

Become EABM
Become Reviewer
Call for Editor


The ongoing emergence of bacterial strains resistant to even third- and fourth-generation β-lactam antibiotics is one of the most pressing and challenging issues in clinical therapy. Furthermore, under the pressure of antibiotics used ubiquitously over the last 80 years, functional mutations and new resistances are continuously increasing. Therefore, new drugs and new approaches to the infections produced by multidrug-resistant Gram-negative bacteria are categorically necessary and expected by the scientific community. This review describes the most deleterious known extended-spectrum β- lactamases and the molecules now available for targeting bacterial infections. The active-site chemical and geometric properties that are potentially exploitable for the design of both broad-spectrum and selective compounds are described.

Keywords: β-lactam antibiotics, β-lactamase binding site, β-lactamase inhibitors, carbapenemase, extended spectrum β- lactamases, molecular interaction fields, resistance.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 18 March, 2014
Page: [1405 - 1434]
Pages: 30
DOI: 10.2174/09298673113206660323
Price: $65

Article Metrics

PDF: 58